FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
The FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday regarding recommendations for reauthorizing the Prescription Drug User Fee Act the day after launching its TrialBlazer initiative. Meanwhile, Definium Therapeutics notched another late-stage trial win for its LSD drug, and Novartis continues to reel from the company’s triple asset stumble.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from BioSpace
When vision fades: Rethinking wet AMD and the durability gap
The supply chain fault lines of modern pharma
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
Breaking borders: Building biotech scale in Benelux
Get summaries like this every morning.
Free AI-powered recaps of BioSpace and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.